SinoMab BioScience Limited (HKG:3681)
Hong Kong · Delayed Price · Currency is HKD 1.950
-0.030 (-1.52%)
At close: Mar 6, 2026
SinoMab BioScience Market Cap
SinoMab BioScience has a market cap or net worth of 2.7 billion as of March 6, 2026. Its market cap has increased by 121.13% in one year.
Market Cap
2.70B
Enterprise Value
2.99B
Revenue
6.28M
Ranking
n/a
PE Ratio
n/a
Stock Price
1.95
Market Cap Chart
Since November 12, 2019, SinoMab BioScience's market cap has decreased from 6.04B to 2.70B, a decrease of -55.21%. That is a compound annual growth rate of -11.94%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Mar 6, 2026 | 2.70B | 45.52% |
| Dec 31, 2025 | 1.86B | 56.14% |
| Dec 31, 2024 | 1.19B | -31.56% |
| Dec 29, 2023 | 1.74B | -7.18% |
| Dec 30, 2022 | 1.87B | -34.91% |
| Dec 31, 2021 | 2.88B | -37.83% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Nov 12, 2019 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Viva Biotech Holdings | 4.20B |
| TYK Medicines | 3.94B |
| AIM Vaccine | 3.64B |
| Qyuns Therapeutics | 3.61B |
| Medtide | 3.16B |
| BioDlink International Company | 3.11B |
| Jiangsu Recbio Technology | 2.65B |
| Antengene Corporation | 2.62B |